Payment overview · 2025
General Payments
$956.63
45 reported records · 14 companies
Healthcare provider profile · identity verified
Kathryn Thelen, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · HOLDREGE, NE · NPI 1104209337
Verified facts
What the public records show
CMS Open Payments records show Kathryn Thelen, D.O. received $956.63 in general payments during 2025 across 45 reported records.
AstraZeneca Pharmaceuticals LP accounted for 38.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Zenpep by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $370.19 | 38.7% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $300.79 | 31.4% | 18 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.17 | 3.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $34.25 | 3.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.14 | 3.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.03 | 3.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $30.00 | 3.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.74 | 3.0% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.86 | 2.1% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $18.66 | 1.9% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.27 | 1.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.74 | 1.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.05 | 1.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $4.74 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $956.63 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $188.45 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $170.09 | 16 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $161.39 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $103.43 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $37.17 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $37.17 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $37.17 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $34.25 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.14 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.14 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.03 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $30.00 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $28.74 | 2 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $5.70 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $4.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
147 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 414 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 334 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 299 | 45 |
| Omeprazole | Omeprazole | 258 | 35 |
| Lisinopril | Lisinopril | 227 | 38 |
| Sertraline Hcl | Sertraline Hcl | 212 | 34 |
| Losartan Potassium | Losartan Potassium | 198 | 28 |
| Montelukast Sodium | Montelukast Sodium | 193 | 27 |
| Donepezil Hcl | Donepezil Hcl | 174 | 21 |
| Furosemide | Furosemide | 168 | 32 |
| Potassium Chloride | Potassium Chloride | 162 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 162 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 159 | 36 |
| Carvedilol | Carvedilol | 156 | 18 |
| Eliquis | Apixaban | 147 | 14 |
| Tramadol Hcl | Tramadol Hcl | 143 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 142 | 25 |
| Gabapentin | Gabapentin | 138 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 15 |
| Metformin Hcl | Metformin Hcl | 117 | 22 |
| Famotidine | Famotidine | 114 | 23 |
| Warfarin Sodium | Warfarin Sodium | 111 | 15 |
| Spironolactone | Spironolactone | 104 | 17 |
| Trazodone Hcl | Trazodone Hcl | 97 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 17 |
| Celecoxib | Celecoxib | 87 | 15 |
| Simvastatin | Simvastatin | 81 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 26 |
| Chlorthalidone | Chlorthalidone | 72 | suppressed |
| Jardiance | Empagliflozin | 70 | 11 |
| Prednisone | Prednisone | 68 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 11 |
| Pregabalin | Pregabalin | 60 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 57 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 54 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 51 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | suppressed |
| Meloxicam | Meloxicam | 49 | 13 |
| Mirtazapine | Mirtazapine | 47 | suppressed |
| Fentanyl | Fentanyl | 45 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | 11 |
| Synthroid | Levothyroxine Sodium | 44 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | 26 |
| Cephalexin | Cephalexin | 37 | 13 |
| Lorazepam | Lorazepam | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Ozempic | Semaglutide | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 17 |
| Torsemide | Torsemide | 29 | suppressed |
| Allopurinol | Allopurinol | 28 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Metolazone | Metolazone | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Cefdinir | Cefdinir | 25 | 22 |
| Mupirocin | Mupirocin | 25 | 23 |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 11 |
| Ondansetron Odt | Ondansetron | 24 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 20 | 14 |
| Azithromycin | Azithromycin | 20 | 19 |
| Cilostazol | Cilostazol | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 19 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 11 |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Nyamyc | Nystatin | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 12 | 12 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $956.63 · 45 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BOTOX, BREZTRI, BodyGuardian, CAPLYTA, COMIRNATY, FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax, Kerendia, LEQVIO, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, VOQUEZNA, VRAYLAR, Veozah, XIFAXAN, ZENPEP | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error